DE · CBHD.DE
Coloplast A/S
- Sector
- Healthcare · Medical - Equipment & Services
- Headquarters
- Humlebaek
- Website
- coloplast.dk
Price · as of 2025-09-30
$52.56
Market cap 14.67B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $10.80 | -79.45% |
| Intrinsic Value(DCF) | $26.76 | -49.09% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $23.30 | -55.67% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.24 | $17.90 | $5.24 | $4.20 | $16.80 |
| 2012 | $1.44 | $19.24 | $15.17 | $4.70 | $22.60 |
| 2013 | $9.12 | $24.62 | $15.77 | $0.00 | $23.30 |
| 2014 | $6.88 | $23.46 | $9.32 | $0.00 | $22.20 |
| 2015 | $8.33 | $19.42 | $2.83 | $0.00 | $11.20 |
| 2016 | $8.65 | $36.11 | $22.12 | $0.00 | $26.80 |
| 2017 | $11.38 | $37.88 | $30.51 | $0.00 | $32.80 |
| 2018 | $18.68 | $38.25 | $21.62 | $0.00 | $33.70 |
| 2019 | $28.62 | $43.87 | $24.34 | $0.00 | $40.90 |
| 2020 | $43.54 | $53.74 | $25.30 | $0.00 | $30.10 |
| 2021 | $59.51 | $66.32 | $24.18 | $0.00 | $38.60 |
| 2022 | $55.07 | $74.63 | $27.62 | $0.00 | $70.10 |
| 2023 | $52.07 | $74.77 | $33.35 | $0.00 | $48.60 |
| 2024 | $71.36 | $84.48 | $31.50 | $0.00 | $54.40 |
| 2025 | $59.89 | $80.99 | $8.36 | $0.00 | $23.30 |
AI valuation
Our deep-learning model estimates Coloplast A/S's (CBHD.DE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $10.80
- Current price
- $52.56
- AI upside
- -79.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$26.76
-49.09% upside
Graham-Dodd
—
— upside
Graham Formula
$23.30
-55.67% upside
About Coloplast A/S
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
- CEO
- Lars Soren Rasmussen
- Employees
- 16.74K
- Beta
- 0.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($26.76 ÷ $52.56) − 1 = -49.09% (DCF, example).